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ABSTRACT
Objective: To evaluate whether a model that was
previously developed to predict 14-day mortality for
nursing home residents with dementia and lower
respiratory tract infection who received antibiotics
could be applied to residents who were not treated
with antibiotics. Specifically, in this same data set, to
update the model using recalibration methods; and
subsequently examine the historical, geographical,
methodological and spectrum transportability through
external validation of the updated model.
Design: 1 cohort study was used to develop the
prediction model, and 4 cohort studies from 2
countries were used for the external validation of the
model.
Setting: Nursing homes in the Netherlands and the
USA.
Participants: 157 untreated residents were included
in the development of the model; 239 untreated
residents were included in the external validation
cohorts.
Outcome: Model performance was evaluated by
assessing discrimination: area under the receiver
operating characteristic curves; and calibration: Hosmer
and Lemeshow goodness-of-fit statistics and
calibration graphs. Further, reclassification tables
allowed for a comparison of patient classifications
between models.
Results: The original prediction model applied to the
untreated residents, who were sicker, showed excellent
discrimination but poor calibration, underestimating
mortality. Adjusting the intercept improved calibration.
Recalibrating the slope did not substantially improve
the performance of the model. Applying the updated
model to the other 4 data sets resulted in acceptable
discrimination. Calibration was inadequate only in one
data set that differed substantially from the other data
sets in case-mix. Adjusting the intercept for this
population again improved calibration.
Conclusions: The discriminative performance of the
model seems robust for differences between settings.
To improve calibration, we recommend adjusting the
intercept when applying the model in settings where
different mortality rates are expected. An impact study
may evaluate the usefulness of the two prediction
models for treated and untreated residents and whether
it supports decision-making in clinical practice.
INTRODUCTION
Lower respiratory tract infections (LRI),
including pneumonia, are an important
cause of death in nursing home residents
and may be the ultimate cause of death in
one-third to two-thirds of patients with
Strengths and limitations of this study
▪ An existing prediction model for treated residents
was updated and validated for untreated resi-
dents, thus combining prior knowledge on pre-
dictors of 14-day mortality for nursing home
residents with dementia and lower respiratory
tract infections treated with antibiotics with new
knowledge on residents not treated with
antibiotics.
▪ The generalisability of the updated model for the
untreated residents was evaluated by externally
validating the model in four data sets from two
countries, allowing for an evaluation of the his-
torical, geographical, methodological and spec-
trum validity of the model.
▪ Through adjustment of the intercept only, the
model was generalisable to different settings
which supports the principle of a stepwise
approach using cumulative data to improve prog-
nostic modelling.
▪ The relatively small sample sizes of the data sets
did not allow for re-estimating the predictors or
for extending the original prediction model by
adding new predictors; however, recalibration
methods may suffice to improve model
performance.
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dementia.1–4 Physicians and families involved in the care
of patients with dementia often must decide whether or
not to treat LRI, and patients’ wishes are often unclear.5
A variety of factors relate to the decision to withhold
antibiotic treatment, and these may differ by country;
for example, in the USA, sicker patients are more likely
to be treated, whereas the reverse is true in the
Netherlands.6
To inform prognosis and support physicians in decision-
making, a prediction model was previously developed in a
Dutch population of nursing home residents with demen-
tia and LRI (more speciﬁcally, a physician’s diagnosis of
pneumonia, mostly without X-ray),3 predicting mortality
within 14 days for residents treated with antibiotics. The
model showed good discrimination and adequate calibra-
tion in the Dutch development population.3 This model
was validated externally in a US study population of resi-
dents with LRI in which discrimination was good and cali-
bration was adequate.3 However, a clinical impact study
indicated that physicians perceived usefulness in practice
as suboptimal because the prediction was valid only for
residents treated with antibiotics.7 The current study there-
fore aims to deﬁne a model that can adequately predict
mortality in nursing home residents with dementia and
LRI who are not treated with antibiotics.
Predicting a particular outcome may start with existing
prediction models rather than developing new predic-
tion models for each new data set, because in this way,
prior knowledge is combined with new knowledge.8 9
Furthermore, for clinical practice, it is impractical to
have a variety of competing models to choose from. For
instance, more than 60 models have been developed
that predict breast cancer prognosis10 and more than
100 models that predict outcome after brain trauma.11
We previously found that, despite profound differences
between residents treated with and residents treated
without antibiotics, predictors for mortality within 1
week were largely similar between those two groups.12
Therefore, rather than developing yet another predic-
tion model, our aim was to evaluate whether the model
that was previously developed to predict 14-day mortality
for nursing home residents with dementia and LRI who
received antibiotics3 could be applied to residents who
were not treated with antibiotics. In this way, spectrum
transportability of the original model was studied. In
addition, our aims were to examine whether the model
performance in the untreated residents improves by
applying available updating strategies,9 13–15 and to
externally validate this updated model in four other data
sets, thus studying the historical, geographical, methodo-
logical and spectrum transportability of the updated
model.
METHODS
Description of the development data set
The Dutch Pneumonia Study prospectively included 706
nursing home residents in 61 nursing homes between
October 1996 and July 1998.12 16 The inclusion criteria
were (1) psychogeriatric disease (almost all dementia);
(2) nursing home residence for ≥4 weeks; and (3) pneu-
monia diagnosis as judged by a physician (mostly
without X-ray).
For this study, we only included residents who were
not treated with antibiotics (n=165). We excluded resi-
dents who did not have a diagnosis of dementia (n=6),
with unknown mortality status (n=1), and one resident
who had missing values on 4 of the 8 predictors, result-
ing in 157 eligible cases for analyses.
Description of the external validation data sets
To externally validate the prediction model, four data
sets were used. The Missouri Lower Respiratory
Infection (LRI) Study prospectively included 1406 epi-
sodes of LRI in 1044 nursing home residents in 36
nursing homes between August 1995 and September
1998.17 18 We selected the episodes of residents who
were not treated with antibiotics (n=254). We excluded
episodes without a dementia diagnosis (n=78). The
Missouri LRI Study deﬁned dementia as either a diagno-
sis of dementia or a score of ≥3 on the MDS Cognitive
Performance Scale.3 19 Eligible cases (176) represented
162 residents.
The ‘Dutch 2006–2007’ study prospectively included
72 nursing home residents in 54 nursing homes
between July 2006 and August 2007.20 21 Of these 54
nursing homes, 53 previously participated in the Dutch
Pneumonia Study. We selected the residents not treated
with antibiotics (n=15). We excluded residents without a
dementia diagnosis (n=1) or with unknown mortality
status (n=1). There were 13 cases eligible for analyses.
The ‘Bedford US’ study prospectively included 110
episodes of LRI in 94 nursing home residents in the
dementia special care unit of a US Department of
Veterans Affairs nursing home between February 2004
and November 2008.22 All residents were diagnosed with
dementia. We selected the episodes untreated with anti-
biotics (n=25). There were 25 eligible cases in 25 resi-
dents for analyses.
Of the Dutch End of Life in Dementia (DEOLD)
study, we included 155 episodes of 110 nursing home
residents identiﬁed prospectively or retrospectively after
death in 34 nursing homes between January 2007 and
March 2010.23 All residents were diagnosed with demen-
tia. We selected the episodes untreated with antibiotics
(n=25). There were 25 eligible cases in 24 residents for
analyses.
All studies have been approved by the local medical
ethics committees and, when this was deemed necessary
by the medical ethics review committee, family or
proxies provided informed consent.
Original prediction model
The original prediction model was developed in the
Dutch Pneumonia Study in nursing home residents with
dementia and LRI who were treated with antibiotics,3 to
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predict 14-day mortality (table 1). The model included:
gender (male/female), respiratory rate (breaths per
minute), respiratory difﬁculty (yes/no), pulse rate
(beats per minute), decreased alertness (yes/no), insuf-
ﬁcient ﬂuid intake (yes/no), eating dependency (inde-
pendent/need for assistance/fully dependent) and
pressure sore (any grade; yes/no). Respiratory rates and
pulse rates were truncated at 12 and 60 breaths per
minute and at 50 and 160 beats per minute, respectively,
to avoid undue inﬂuence of outliers (the latter value was
not exceeded in the data used for this study).
This prediction model showed excellent discrimin-
ation (area under the receiver operating characteristic
curve (AUC)=0.80) and adequate calibration (Hosmer
and Lemeshow (H&L) goodness-of-ﬁt statistic: p=0.23)
in the Dutch development population.3 After internal
validation of the model using bootstrapping techniques,
external validation in a US population showed accept-
able discrimination (AUC=0.74) and adequate calibra-
tion (H&L statistic: p=0.67).3
Developing the model for antibiotic-untreated residents
Step 1: Validation of the original prediction model in
untreated residents
First, we tested whether the original prediction model
for residents treated with antibiotics3 was also valid for
residents of the Dutch Pneumonia Study who were not
treated with antibiotics. Prior research in this study
population has shown that the residents not treated with
antibiotics are more severely ill and have higher mortal-
ity than the residents who were treated with antibio-
tics.12 16 Therefore, we anticipated a need to update the
model that was developed and internally validated for
the residents treated with antibiotics to improve model
performance in the residents not treated with
antibiotics.
Step 2: Updating of the original prediction model
After applying the original prediction model to the
untreated residents of the Dutch Pneumonia Study, the
same data set was used to update the model according
to the new case-mix of untreated residents, thus improv-
ing the performance of the model for the untreated
residents. Steyerberg14 describes eight different methods
to update a prediction model, including methods for
recalibration, model revision and model extension.
In our study, we employed methods for recalibration.
First (update 1), the intercept of the original prediction
model was recalibrated: the regression coefﬁcients of
the original prediction model were applied to the
untreated residents of the Dutch Pneumonia Study,
ﬁxed at their original values, while the intercept was the
only free parameter. Thus, we corrected for differences
in mortality rate between treated and untreated
residents.
Second (update 2), the intercept and the overall cali-
bration slope were recalibrated: the linear predictor (LP)
was calculated for each patient by multiplying the values
of the regression coefﬁcients of the original prediction
model by the values of the corresponding predictor vari-
ables for each individual patient. Next, a prediction
model was constructed with only the LP as a predictor,
estimating two parameters: an intercept and a regression
coefﬁcient for the LP (ie, the calibration slope or the
shrinkage factor). This recalibrates the original regres-
sion coefﬁcients.
We refrained from additional steps, such as
re-estimating the predictors and extending the model
with new predictors, to avoid problematic overﬁtting of
coefﬁcients due to our relatively small sample (n=157
untreated cases in the development data set).
Step 3: External validation of the updated model
Finally, the updated model was externally validated in
four data sets: the Missouri LRI Study, the Dutch 2006–
2007 study, the Bedford US study and the DEOLD study.
Owing to considerable differences in resident character-
istics and in the LRI deﬁnition between the Missouri
LRI Study (LRI assessed by project nurses using clinical
criteria) and the other three studies (physician’s diagno-
sis of pneumonia), the model was validated separately in
the Missouri LRI Study and in the other three data sets
combined.
Validation studies can address several types of trans-
portability: historical/temporal, geographical, methodo-
logical and spectrum/domain transportability.9 14 24
Residents in the Missouri LRI Study were historically
comparable to residents in the development data set
(1995−1998 vs 1996−1998), but these data sets differed
in geographical (USA vs the Netherlands) and methodo-
logical aspects (different diagnosis of LRI) and in
case-mix (table 2). This enabled a study of the geo-
graphical, methodological and spectrum transportability
of the updated model with data from the Missouri LRI
Study.
Residents in the Dutch 2006–2007 study, the Bedford
US study and the DEOLD study (hereafter referred to as
the three combined external validation data sets) differed
from residents in the development data set in historical
Table 1 Original prediction model for treated residents3
(logistic regression model, after internal validation)
Predictor Regression coefficient
Intercept −6.263
Male gender 0.447
Respiratory rate (per unit) 0.027
Respiratory difficulty (y/n) 0.667
Pulse rate (per unit) 0.019
Decreased alertness (y/n) 0.692
Insufficient fluid intake (y/n) 0.561
Eating dependency* 0.771
Pressure sore (y/n) 0.557
*Per point more dependent on a 3-point scale (0, independent; 1,
need for assistance; 2, fully dependent).
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aspects (2006−2007, 2004−2008, 2007−2010 vs 1996
−1998) but were comparable to residents in the develop-
ment data set in methodological and spectrum aspects.
Geographically, residents of the Dutch 2006–2007 study
were very similar to residents of the development data set
because 53 of the 54 participating nursing homes in the
Dutch 2006–2007 study participated in the Dutch
Pneumonia Study (the development data set). The
DEOLD study was mostly conducted in different Dutch
nursing homes than in the other two Dutch studies,
whereas the Bedford US study was conducted in the USA.
Therefore, the three combined external validation data
sets enable a study of historical and, to some extent, geo-
graphical transportability of the updated model.
Statistical analyses
Comparing samples
Differences in resident characteristics between the devel-
opment data set, the Missouri LRI Study and the three
combined external validation data sets were tested using
χ2 tests for dichotomous variables, χ2 tests for trend for
ordinal categorical variables and independent-samples
t-tests for continuous variables.
Model performance
To evaluate the performance of the original prediction
model applied to the untreated residents of the Dutch
Pneumonia Study (step 1), the performance of the two
updated models (ie, recalibration of intercept only, and
slope combined with the intercept) in the Dutch
Pneumonia Study (step 2) and the performance of the
updated model in the external validation data sets (step
3), discrimination and calibration were assessed. For dis-
crimination, AUCs were assessed, considering AUCs of
0.70–0.79 to indicate acceptable, 0.80–0.89 to indicate
excellent and >0.90 to indicate outstanding discrimin-
ation.25 Calibration was assessed by H&L statistics (non-
signiﬁcant values indicate adequate calibration) and by
calibration graphs, comparing observed and predicted
mortality rates in deciles of the predicted mortality risk.
Further, the added value of the new intercept (update
1) or calibration slope (update 2) was tested for signiﬁ-
cance using the Wald-statistic, and difference in overall
performance between two models was assessed using a
likelihood-ratio test (LR-test).
In addition, reclassiﬁcation tables were produced to
compare classiﬁcations of patients as low or high risk
between the old and new models, that is, whether
patients were better classiﬁed using the new models.26
Next, the net reclassiﬁcation index (NRI) was calcu-
lated,26 using a cut-off point of 80% to deﬁne low versus
high mortality risk. This cut-off point was chosen
because a survey study showed that 73% of the clinicians
considered mortality risks of 75–90% as sufﬁciently high
to justify withholding antibiotics.20 NRI for events was
calculated as the proportion of events classiﬁed up
(ie, from <80% to ≥80%) minus the proportion of
events classiﬁed down, and can be interpreted as the
improvement in sensitivity between the two different
models.26 27 NRI for non-events was calculated as the
proportion of non-events classiﬁed down minus the pro-
portion of non-events classiﬁed up, and can be
Table 2 Description of the development and external validation patient data sets
Data set
Resident characteristic
Dutch Pneumonia Study
(development data set) Missouri LRI Study
Three combined external
validation data sets*
Number of untreated patients 157 176 63
14-day mortality, number (%) 138 (87.9) 24 (13.6)†‡ 51 (81.0)
Age, mean (SD); range 82.6 (7.8); 59–98 85.2 (8.1); 60–104†‡ 82.9 (6.0); 67–99
Dementia severity/cognitive performance,
mean score (SD)
BANS-S 20.5 (3.9) CPS 4.5 (1.3) −
Gender, % female 61.8% 81.3%†‡ 33.3%†
Respiratory rate, mean (SD); range§ 29.8 (9.3); 12–60 26.5 (6.7); 12–44 †‡ 29.3 (8.4); 12–56
Respiratory difficulty, % 66.2% 19.3%†‡ 77.8%
Pulse rate, mean (SD); range¶ 97.6 (17.8); 50–144 85.3 (14.9); 52–140†‡ 92.6 (17.9); 50–148
Decreased alertness, % 75.2% 27.3%†‡ 79.4%
Insufficient fluid intake, % 78.3% 8.0%†‡ 74.6%
Eating dependency, %
Independent 0.6% 10.8%†‡ 4.8%†
Need for assistance 5.7% 50.0% 22.2%
Fully dependent 93.6% 39.2% 73.0%
Pressure sore, % 28.0% 11.4%† 20.6%
*Three combined external validation data sets: the Dutch 2006–2007 study, the Bedford US study and the DEOLD study combined.
†Significantly different (p<0.05) compared with the Dutch Pneumonia Study; tested with t-tests for continuous, χ2 for dichotomous and χ2
including test for trend for categorical variables.
‡Significantly different (p<0.05) compared with the three combined external validation data sets.
§Truncated at 12 and 60 breaths per minute.
¶Truncated at 50 beats per minute.
BANS-S, Bedford Alzheimer Nursing Severity-Scale;31 CPS, Cognitive Performance Scale.19
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interpreted as the improvement in speciﬁcity between
the two different models.26 27 Total NRI was the sum of
NRI for events and NRI for non-events and could theor-
etically range from −2 (if sensitivity and speciﬁcity
would deteriorate from 100% to 0%) to +2 (if sensitivity
and speciﬁcity would improve from 0% to 100%).
Finally, sensitivity, speciﬁcity, positive predictive value
(PPV) and negative predictive value (NPV) were calcu-
lated using the same cut-off of 80% to compare classiﬁ-
cations of patients as low or high risk between the
original and the updated models.
Missing predictor values
Consistent with the imputation strategy that was used
previously in the Dutch Pneumonia Study and the
Missouri LRI Study,3 we used the same imputation strat-
egy in this study: for the continuous variables, respira-
tory rate (17.8% missing) and pulse rate (19.1%
missing), hot-deck imputation was applied, using the
variables tachypnoea and tachycardia, respectively. For
dichotomous and categorical variables (<2.5% missing
per variable), modes were imputed.
Sensitivity analysis
In the Missouri LRI Study and in the DEOLD study, mul-
tiple episodes could be included per resident. To evalu-
ate whether the inclusion of multiple episodes per
resident could have affected our results, we assessed the
performance of the updated model in subsets of the
external validation data sets including only the ﬁrst
episode for each resident (14 and 1 episode were
removed in the Missouri LRI Study and in the DEOLD
study, respectively).
Significance and software
A two-sided p value of <0.05 was considered statistically
signiﬁcant. Statistical analyses were performed using
SPSS V.19 and R software V.2.15.0, using the packages
‘rms’, ‘pROC’ and ‘ResourceSelection’.
RESULTS
Resident characteristics
Several resident characteristics differed between the data
sets (table 2 and online supplementary table SA). In the
development data set, 14-day mortality was 87.9%.
Among the external validation data sets, 14-day mortality
was lowest in the Missouri LRI Study (13.6%) and
highest in the Dutch 2006–2007 study (92.3%).
Residents in the Missouri LRI Study were signiﬁcantly
older, more often female and less severely ill compared
to residents of either the development data set or the
three combined external validation data sets. The per-
centage of pressure sores was lower in the Missouri LRI
Study. Residents in the three combined external valid-
ation data sets were signiﬁcantly less often fully depend-
ent in eating and more often male (with the Bedford
US study including mostly male residents) than residents
in the development data set.
Step 1: validation of the original prediction model
The original prediction model applied to the untreated
residents of the Dutch Pneumonia Study showed excel-
lent predictive performance (AUC=0.80, 95% CI 0.79 to
0.82; table 3). However, calibration was poor (H&L statis-
tic: p<0.001) and the calibration plot showed that pre-
dicted values were systematically too low (ﬁgure 1A).
Based on a cut-off point of 80%, speciﬁcity was 100%,
but sensitivity was only 1%.
Step 2: updating of the original prediction model
Consistent with the underestimation of mortality in the
previous step, we found that updating the intercept
(update 1) resulted in an increase in the intercept of
2.66 (table 3), and adding this new intercept to the
model led to a signiﬁcant Wald-statistic (p<0.001, not
shown). The calibration plot improved considerably
(ﬁgure 1B) and the H&L statistic showed adequate ﬁt
(p=0.38). Since the ranking of the predicted probabil-
ities is not affected by the updated intercept, discrimin-
ation did not change. Reclassiﬁcation of the ﬁrst
updated model compared with the original prediction
model (cut-off 80%) showed that 84% of the events
were reclassiﬁed from low risk (<80%) to high risk
(≥80%), and thus were reclassiﬁed correctly, but also
53% of the non-events were reclassiﬁed from low risk to
high risk, and thus were reclassiﬁed incorrectly (tables 4
and 5), resulting in an NRI of 0.31 (p=0.01). Sensitivity
increased to 85%, although speciﬁcity decreased to
47%. This led to a decrease in PPV from 100% to 92%
and an increase in NPV from 12% to 30%.
The model with the updated intercept and calibration
slope (update 2) resulted in a non-signiﬁcant
Wald-statistic for the new calibration slope (p=0.30, not
shown) and no signiﬁcant improvement in overall
model performance (LR-test p=0.28). Further, the H&L
statistic showed adequate ﬁt (p=0.35), but the calibra-
tion plot deteriorated compared with the model includ-
ing only an updated intercept (ﬁgure 1C). Again, the
ranking of the predicted probabilities, and thus discrim-
ination, did not change. Reclassiﬁcation of the model
including a recalibrated intercept and slope compared
with the model including a recalibrated intercept
showed only minor improvement: 5% of the non-events
were reclassiﬁed from high risk to low risk; speciﬁcally,
one non-event was reclassiﬁed correctly (table 6).
Finally, there was no change in sensitivity and only
minor improvement in speciﬁcity from 47% to 53%.
Therefore, we selected the model with the updated
intercept only (update 1) for external validation (see
online supplementary table SB).
Step 3: external validation of the updated model
Applying the updated model to the Missouri LRI Study
showed that discrimination was acceptable (AUC=0.76,
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95% CI 0.74 to 0.78), but the predicted probabilities
were systematically too high (ﬁgure 1D), and the ﬁt was
inadequate (H&L statistic: p<0.001; table 7). We there-
fore examined whether updating the intercept for this
data set would improve model performance. Consistent
with the overestimation of mortality in this data set, we
found that updating the intercept resulted in a signiﬁ-
cant decrease of 2.407 (p<0.001; data not shown),
leading to a ﬁnal intercept of −6.014 (online supple-
mentary table SB). Applying this new model to the
Missouri LRI Study resulted in an improvement in cali-
bration, statistically (H&L statistic: p=0.16, not shown)
and visually (ﬁgure 1E).
In the three combined external validation data sets
(table 5), discrimination was excellent (AUC=0.83, 95%
CI 0.79 to 0.86). The H&L statistic indicated that calibra-
tion was adequate (p=0.09), although the calibration
plot (ﬁgure 1F) showed that predicted values were over-
estimated for residents with lower observed probabilities.
Again, we examined whether updating the intercept for
this data set would improve model performance.
Updating the intercept resulted in a small non-
signiﬁcant decrease in the intercept of 0.38 (p=0.28;
data not shown). Although this update improved
calibration statistically (H&L statistic: p=0.25; data not
shown), the calibration plot showed only a small
improvement (ﬁgure 1G), and reclassiﬁcation of this
model compared with the previous model showed that
18% of the events were reclassiﬁed from high risk to
low risk (data not shown), and thus were reclassiﬁed
incorrectly, while 8% of the non-events were reclassi-
ﬁed correctly, resulting in an NRI of −0.09 (p=0.36).
Since the calibration plot showed overestimation of the
predicted values for residents in the three combined
external validation data sets with lower observed prob-
abilities (ﬁgure 1F, G), we additionally examined
whether updating the calibration slope would improve
the model for these data sets. However, this resulted in
a non-signiﬁcant Wald-statistic for the new calibration
slope (p=0.26; data not shown) and no signiﬁcant
improvement in overall model performance (LR-test
p=0.22).
Sensitivity analysis
Applying the updated model to a subset of the Missouri
LRI Study including only the 162 ﬁrst episodes did not
lead to substantial differences in the performance of the
model: AUC=0.75 (95% CI 0.73 to 0.77), H&L statistic:
Table 3 Model performance in the Dutch Pneumonia Study (development data set)
Step 2
Step 1 Update 1 Update 2
Discrimination
AUC (95% CI) 0.80 (0.79 to 0.82) 0.80 (0.79 to 0.82) 0.80 (0.79 to 0.82)
Sensitivity 1% 85% 85%
Specificity 100% 47% 53%
PPV 100% 92% 93%
NPV 12% 30% 32%
Calibration (H&L statistic*)
χ2 178.6 8.6 8.9
p Value <0.001 0.38 0.35
Overall performance (LR-test)
χ2 − − 1.18†
p Value − − 0.28
Reclassification
NRI‡ − 0.31§ 0.05†
p Value − 0.09 0.32
Parameters
Model intercept¶ −6.263 −3.607 −5.359
Calibration intercept** − 2.656 0.904
Calibration slope†† − − 1.33
Step 1: Original prediction model applied to untreated residents.
Step 2: Updating the original model.
Update 1: recalibrating intercept.
Update 2: recalibrating intercept and slope.
*H&L statistic: non-significant p values indicate adequate fit.
†Compared with update 1.
‡Cut-off point 80%.
§Compared with step 1.
¶Intercept of the new model, after updating.
**Deviation from original intercept (−6.263).
††To recalibrate the original regression coefficients, all original regression coefficients are multiplied by the calibration slope or shrinkage
factor.
AUC, area under the curve; H&L statistic, Hosmer and Lemeshow goodness-of-fit statistic; LR-test, likelihood ratio test; NPV, negative
predictive value; NRI, net reclassification index; PPV, positive predictive value; χ2: Chi-square.
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p<0.001. Similarly, for the three combined external val-
idation data sets, applying the updated model to a
subset including only the 62 ﬁrst episodes did not lead
to substantial differences in the performance of the
model: AUC=0.83 (95% CI 0.79 to 0.86), H&L statistic:
p=0.052.
DISCUSSION
Our aim was to evaluate whether a previously developed
model that predicts short-term mortality in nursing
home residents with dementia and LRI treated with anti-
biotics3 could be applied to residents who were not
treated with antibiotics. We found that in the
Figure 1 Calibration plots. The dotted line indicates perfect calibration. The triangles represent the observed and predicted
mortality rates in deciles of the predicted mortality risk. The solid line is a smoothed spline curve. (A) Calibration plot of the
original prediction model applied to untreated residents of the Dutch Pneumonia Study (step 1). (B) Calibration plot of update 1:
model with recalibrated intercept applied to untreated residents of the Dutch Pneumonia Study (step 2). (C) Calibration plot of
update 2: model with recalibrated intercept and calibration slope applied to untreated residents of the Dutch Pneumonia Study
(step 2). (D) Calibration plot of external validation: model with recalibrated intercept applied to untreated residents of the Missouri
LRI Study (step 3). (E) Calibration plot of additional update: model with additional recalibration of the intercept for the untreated
residents of the Missouri LRI Study. (F) Calibration plot of external validation: model with recalibrated intercept applied to
untreated residents of the three combined external validation data sets (step 3). (G) Calibration plot of additional update: model
with additional recalibration of the intercept for the untreated residents of the three combined external validation data sets.
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development cohort, the Dutch Pneumonia Study, dis-
crimination was excellent in the untreated residents, but
calibration was poor and mortality was underestimated.
This may relate to the fact that the untreated residents
were, compared with the treated residents, more severely
ill on average and also had a higher mortality rate.
Updating the model using recalibration methods
improved calibration in the untreated residents. This
indicates that the discriminative performance of the ori-
ginal prediction model may be robust for differences in
spectrum aspects, while calibration may be inadequate
in new settings and require correction for differences in
mortality rates.
In line with this, external validation of the updated
model in the Dutch 2006–2007 study, the Bedford US
study and the DEOLD study combined—populations
with a case-mix and a mortality rate similar to the Dutch
Pneumonia Study—showed an excellent discrimination
and adequate calibration. However, in the Missouri LRI
Study, where the untreated residents were less severely ill
and the mortality rate was much lower compared with the
other data sets, the updated model showed acceptable
discrimination but inadequate calibration, systematically
overestimating mortality. Nevertheless, an additional
update of the intercept in this population improved cali-
bration considerably. We conclude that while the discrim-
inative performance of the updated model is robust for
differences in historical, geographical, methodological
and spectrum aspects between settings, calibration can
be inadequate in new settings with different illness sever-
ity and mortality rates. We therefore recommend using
the updated model for untreated residents in populations
with an illness severity and a mortality rate comparable to
the untreated residents of the Dutch Pneumonia Study,
but to update the intercept of the model when applying
the model in a setting with a different illness severity or
where a different mortality rate is expected. For example,
in populations with relatively low illness severity and low
mortality such as the Missouri LRI Study, an intercept of
−6.0 is required (instead of −3.6). Online supplementary
table SB provides examples of how to apply the predic-
tion model in clinical practice.
In the three combined external validation data sets, an
additional update of the intercept was not deemed neces-
sary, although the calibration plot did show overestimated
mortality risks for residents with lower observed risks.
Since the data in this area were sparse (11 residents), we
cannot determine whether this reﬂects random error or
actual overestimated predictions for residents with lower
observed risks. Although updating the intercept resulted
in a small improvement in calibration both statistically
(assessed with the H&L statistic) and visually (assessed
with calibration graphs), it worsened classiﬁcation as low
versus high risk. Physicians may ﬁnd the classiﬁcation of
high-risk or low-risk patients important for clinical prac-
tice,7 which implies that correct classiﬁcation might be
more important for clinical practice than correct calibra-
tion, and therefore this additional update was not an
improvement in this population.
A limitation of this study is that the sample sizes of the
data sets were relatively small, which did not allow for
re-estimating predictors or extension of the original pre-
diction model with new predictors. However, recalibra-
tion methods may sufﬁce to improve model
performance, especially when discrimination is already
adequate in a new setting.8 14 28 In our study, we indeed
Table 4 Reclassification index (number of participants)
Update 1
compared
with original
model
Update 2
compared
with update
1
NRI
(p value)
0.31 (p=0.01) 0.05 (p=0.32)
Events
(n=138)
Classified up 0.84 (116) 0.00 (0)
Classified down 0.00 (0) 0.00 (0)
Non-events
(n=19)
Classified up 0.53 (10) 0.00 (0)
Classified down 0.00 (0) 0.05 (1)
NRI, net reclassification index.
Reclassification based on a cut-off point of 80%.
Original model: original prediction model applied to untreated
residents of the Dutch Pneumonia Study.
Update 1: recalibration intercept.
Update 2: recalibration intercept and slope.
Table 5 Reclassification table: update 1 compared with
original model
Update 1
Original model <80% ≥80% Total
<80% risk
n with event 21 116 137
n without event 9 10 19
≥80% risk
n with event 0 1 1
n without event 0 0 0
Total 30 127 157
Original model: original prediction model applied to untreated
residents.
Update 1: recalibration intercept.
Table 6 Reclassification table: update 2 compared with
update 1
Update 2
Update 1 <80% ≥80% Total
<80% risk
n with event 21 0 21
n without event 9 0 9
≥80% risk
n with event 0 117 117
n without event 1 9 10
Total 31 126 157
Update 1: recalibration intercept.
Update 2: recalibration intercept and slope.
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found that an update of the intercept led to a consider-
able improvement in calibration. Further, two of the data
sets included multiple episodes per resident. However,
sensitivity analysis showed that excluding those multiple
episodes did not considerably change the performance
of the model. Finally, we validated our model in US and
Dutch populations. Another validation study might be
needed before using the model in other countries.
A limitation of using reclassiﬁcation tables and mea-
sures of sensitivity, speciﬁcity, NPV and PPV was that a
cut-off point is needed to deﬁne high versus low risk. We
chose a cut-off point of 80% based on research among
Dutch elderly care physicians,20 but this cut-off may be
highly culturally sensitive. Another cut-off point would
lead to different values of these measures.
A strength of this study is that an existing prediction
model for treated residents was successfully validated and
updated for untreated residents instead of creating another
new prediction model. In this way, prior knowledge on
predictors of 14-day mortality for nursing home residents
with dementia and LRI treated with antibiotics was com-
bined with new knowledge on residents not treated with
antibiotics. Several studies have emphasised the importance
of validating existing models and have expressed concerns
about the fact that validation studies are still rare.8 9 29 30
Moreover, after updating the original model for the
untreated residents, we externally validated it, which has
also been recommended in the literature.8 9 30
The original prediction model was also converted to a
scoring system that can be used in clinical practice. Our
research indicates that the same scoring system could be
used for the untreated residents by adapting the inter-
cept only. In the data sets included in our study, the
decision to either treat a resident or to withhold treat-
ment was not based on randomised study designs. In
contrast, it has been shown that physicians might base
this decision on illness severity, and therefore, the lower
mortality rates for treated compared with untreated
residents are not necessarily the result of their treat-
ment.16 When the two scoring systems are used simultan-
eously in clinical practice, it is important to caution
against incorrect interpretation as to the effect of anti-
biotics in the same (individual) residents.
In conclusion, we demonstrated that the prediction
model that was developed to predict 14-day mortality for
nursing home residents with dementia and antibiotic-
treated LRI3 showed excellent discrimination in nursing
home residents with dementia and LRI who were not
treated with antibiotics, and only required adjustment of
the intercept to improve calibration. Further, the inter-
cept had to be adjusted again when the model for
untreated residents was applied to an untreated popula-
tion that differed substantially in overall mortality. We
therefore conclude that the discriminative performance
of the prediction model seems robust for differences
between settings, and, to improve calibration, recom-
mend adjusting the intercept when applying the model
in a setting where a different mortality rate is expected.
A clinical impact study may evaluate the usefulness of
the two prediction models—the original developed
model for the treated residents and the updated model
for the untreated residents—in clinical practice.
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